<DOC>
	<DOCNO>NCT02081638</DOCNO>
	<brief_summary>Background : - The immune system protect body infection . But also cause harm . For example , clot system make blood clot protect bleed . But blood clot sometimes harmful . People human immunodeficiency virus ( HIV ) infection increase inflammation clotting . This may increase risk disease like stroke heart attack . Researchers want know aspirin HMG-CoA reductase inhibitor ( so-called statin medication ) affect immune clot system people HIV . Aspirin medicine decrease clot . Statins medication give low cholesterol decrease inflammation . Objectives : - To see aspirin statin change immune clot system people HIV . Eligibility : - Adults 18 old HIV low viral load , aspirin statin medication . They must also either : ( 1 ) never take anti-HIV medication ( ARVs ) , suppress viral load , stable CD4 count , never opportunistic infection ; ( 2 ) take ARVs 5 continuous year suppress viral load 3 year . Design : - Participants screen medical history , physical exam , blood lab test . - Participants repeat screen test MRI . An MRI way visualize blood vessel neck head . Participants lie table slide cylinder surround magnetic field . - Participants take either study drug daily 9 month . - Participants blood procedure twice . Blood remove needle one arm circulate machine remove white blood cell . The blood , minus white blood cell , return needle arm . - All participant observe 3 month treatment .</brief_summary>
	<brief_title>Elite Controller ART-treated HIV+ Statin Versus ASA Treatment Intervention Study</brief_title>
	<detailed_description>Despite dramatic improvement mortality antiretroviral therapy ( ART ) , HIV-infected person remain risk develop non-infectious complication , include cardiovascular , renal , neurological disease . A small subset HIV-infected population achieve durable control HIV virus absence ART . These individual , term elite controller ( ECs ) , remain ART na ( SqrRoot ) , stable CD4 T cell count many year history opportunistic infection . Despite lack AIDS complication , recent evidence suggest ECs may exhibit heighten immune activation may contribute potentially increase risk non-infectious complication , similar successfully treated progressors . In current 2 group , randomize , open label trial , intend study effect lipid lower agent v aspirin ( ASA ) immune activation HIV-1 infect participant . One group consist ECs HIV-1 infect , maintain HIV-RNA level less LLD commercially available assay absence ART , history ART opportunistic infection ( OIs ) stable CD4 T cell count great 3 year . The second group enroll HIV-1 infect Treated Progressors ( henceforth refer ART &lt; 50 ) maintain HIV-RNA limit detection commercially available assay ( &lt; 40 , &lt; 48 , &lt; 50 copies/mL ) great 3 year ART ( treatment duration great 4 year ) . Up 2 month screen enrollment visit , group enter 3 month observation period ( establish baseline value biomarkers/cellular marker ) . After 3 month , participant group randomize either ASA , 81 mg PO daily , atorvastatin ( ATV ) , 40 mg ( dose adjust subject antiretroviral regimen significant interaction , treat 9 month , follow 3 month wash period ( see Figure 1 ) . The primary end point change sCD14 9 month study intervention Month 3 Month 12 treatment arm , group combine ( EC ART &lt; 50 ) . Secondary objective compare change soluble biomarkers ( sCD14 , IL-6 , D-dimer , hsCRP , sTF , sCD163 relevad treatment arm ( ASA v statin EC v ART &lt; 50 group combine ) , evaluate cardiovascular ( CV ) disease prevalence EC v ART &lt; 50 group combine ) , evaluate cardiovascular ( CV ) disease prevalence EC v ART &lt; 50 MR imaging carotids , determine MR measurement correlation biomarkers cellular activation marker , investigate change plasma viremia measure single copy assay time .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>INCLUSION CRITERIA : EC Arm 1 . Age great equal 18 year . 2 . Documented HIV1 infection confirm enzymelinked immunosorbent assay ( ELISA ) Western blot test ( repeat perform previously NIH ) . 3 . Categorized long term nonprogressor EC define viral load typically less LLD commercially available assay clinical laboratory criterion ( OIs , ART , stable CD4 T cell count 3 year ) . Viral load blip allow long less 500 copies/mL flank viral load measurement less 100copies/mL . Viral load &lt; 100c/mL acceptable eligibility screening . 4 . In woman childbearing potential , plan pregnancy next 15 month willing use 2 investigator approve highly reliable method birth control consistently study 3 month follow . 5 . Willingness sample store future research . 6 . Not statin ASA past 6 month . ART &lt; 50 Arm 1 . Age great equal 18 year . 2 . Documented HIV1 infection confirm enzymelinked immunosorbent assay ( ELISA ) Western blot test . 3 . In woman childbearing potential , plan pregnancy next 15 month willing use 2 investigator approve highly reliable method birth control consistently study 3 month follow . 4 . On continuous combination ART &gt; 4 year . 5 . HIV RNA &lt; 50 copies/mL ( less 40 less 48 copies/mL , depend low limit detection assay use ; transient period low level ( &lt; 300 ) detectable virus , blip , acceptable isolate follow viral load le low limit detection ) &gt; 3 year current HIVRNA le LLD commercially available assay use . Subject rescreened HIV detectable screen visit . 6 . Willingness sample store future research . 7 . Not statin ASA past 6 month . EXCLUSION CRITERIA 1 . Diagnosis cardiovascular disease hypercholesterolemia ( LDL cholesterol 190 mg/dL ) . 2 . Known hypersensitivity allergy ATV ASA , include history myositis rhabdomyolysis statin ASA use . 3 . Other contraindication ASA statin therapy ( active liver disease , peptic ulcer disease , etc. ) . 4 . Women lactate , pregnant , actively try become pregnant consider pregnancy likely span study ( include woman childbearing potential unwilling use adequate contraception throughout study ) . 5 . Any chronic inflammatory condition either require antiinflammatory medication ( systemic corticosteroid , daily NSAID use , immunomodulating medication ) may , opinion investigator , confound interpretation soluble inflammatory biomarkers . While study , short term ( le 5 day ) NSAID use allow discretion investigator . 6 . Active drug use alcohol abuse , opinion investigator , may interfere ability subject participate study may unacceptably increase risk study intervention.. 7 . Safety laboratory cut offs : coagulation ( INR &gt; 2 upper limit normal [ ULN ] , PLT &lt; 75K ) , renal function ( GFR &lt; 60 ) , liver function ( ALT Alkaline phosphatase direct bilirubin &gt; 2x ULN ) , aldolase &lt; 1.5 ULN anemia ( Hg &lt; 9 mg/dL ) . 8 . Antiretroviral therapy tipranivir , therapy combine nonnucleoside reverse transcriptase inhibitor protease inhibitor . 9 . Chronic hepatitis C coinfection . However , subject 24 week sustain virologic response ( SVR ) , subject consider eligibility . 10 . If either MR apheresis contraindicate , subject may still participate without procedure . In case miss apheresis , 30 mL research blood draw substitute ( see Appendices B C ) . If statin initiation indicate per current guideline , subject counsel consult PMD . If subject chooses take part study , provide PMD pertinent lab result course study , request . Coenrollment Guidelines : Coenrollment trial restrict , enrollment observational study . Study staff notify coenrollment may require approval Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 29, 2016</verification_date>
	<keyword>Immune Activation</keyword>
</DOC>